Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671 | Director · Executive Chairman · 10% owner | August 06, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PHIBRO ANIMAL HEALTH CORP
Report date August 06, 2026 · Filed August 10, 2026
Jointly reported with BFI Co., LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,640 |
Reported balance
After 2026-08-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-06 · Grant · Acquired 12,103 · Balance 26,640 F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. F3: The reported securities are directly held by Jack Bendheim. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee | 56,152 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 56,152 F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.
F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.
F3: The reported securities are directly held by Jack Bendheim.
F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2018 Filed Sep 15, 2018 01:03 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 520 | $45.04 | $23,420.80 |
DisclosureSEC source: 0001144204-18-049579 · tv502904_4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 59,480 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.10, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 12, 2018 Filed Sep 15, 2018 01:03 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-049579 · tv502904_4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 01:26 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 600 | $47.47 | $28,482.00 |
DisclosureSEC source: 0001144204-18-048381 · tv502250_4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.45 to $47.50, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 01:26 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 9,400 | $46.94 | $441,236.00 |
DisclosureSEC source: 0001144204-18-048381 · tv502250_4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,600 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.45 to $47.40, nclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 01:26 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-048381 · tv502250_4.xml · derivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 20,196,034 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 01:26 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $47.30 | $473,000.00 |
DisclosureSEC source: 0001144204-18-048381 · tv502250_4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 40,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.05 to $47.60, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 01:26 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-048381 · tv502250_4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 01:18 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $49.84 | $498,400.00 |
DisclosureSEC source: 0001144204-18-046142 · tv501542_4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.70 to $50.10, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 01:18 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $49.92 | $499,200.00 |
DisclosureSEC source: 0001144204-18-046142 · tv501542_4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 40,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $50.65, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 21, 2018 Filed Aug 24, 2018 01:18 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-046142 · tv501542_4.xml · derivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 20,216,034 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 21, 2018 Filed Aug 24, 2018 01:18 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $50.35 | $503,500.00 |
DisclosureSEC source: 0001144204-18-046142 · tv501542_4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 50,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.90 to $50.65, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 21, 2018 Filed Aug 24, 2018 01:18 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-046142 · tv501542_4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $49.33 | $493,300.00 |
DisclosureSEC source: 0001144204-18-045023 · tv501072_4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.75, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $49.90 | $499,000.00 |
DisclosureSEC source: 0001144204-18-045023 · tv501072_4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 40,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.60 to $50.20, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2018 Filed Aug 16, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 60,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-045023 · tv501072_4.xml · derivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 20,246,034 Underlying: Class A Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2018 Filed Aug 16, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $50.03 | $500,300.00 |
DisclosureSEC source: 0001144204-18-045023 · tv501072_4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 50,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.90 to $50.85, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2018 Filed Aug 16, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-045023 · tv501072_4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $49.82 | $498,200.00 |
DisclosureSEC source: 0001144204-18-042943 · tv500243_form4.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.55 to $50.30, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 12,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-042943 · tv500243_form4.xml · derivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 20,306,034 Underlying: Class A Common Stock · 12,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F4 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 500 | $50.60 | $25,300.00 |
DisclosureSEC source: 0001144204-18-042943 · tv500243_form4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 10,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.55 to $50.70, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 9,500 | $50.09 | $475,855.00 |
DisclosureSEC source: 0001144204-18-042943 · tv500243_form4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 10,500 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.55 to $50.50, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-042943 · tv500243_form4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 06, 2018 Filed Aug 9, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $50.66 | $506,600.00 |
DisclosureSEC source: 0001144204-18-042943 · tv500243_form4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 8,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.05 to $50.95, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 27, 2018 Filed Jul 28, 2018 01:10 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,000 | $47.07 | $188,280.00 |
DisclosureSEC source: 0001144204-18-040562 · tv499481_form4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 18,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.75 to $47.40, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 26, 2018 Filed Jul 28, 2018 01:10 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,000 | $47.61 | $190,440.00 |
DisclosureSEC source: 0001144204-18-040562 · tv499481_form4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 22,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.40 to $47.83, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 25, 2018 Filed Jul 28, 2018 01:10 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,000 | $47.37 | $189,480.00 |
DisclosureSEC source: 0001144204-18-040562 · tv499481_form4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 26,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.10 to $47.60, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,000 | $47.22 | $188,880.00 |
DisclosureSEC source: 0001144204-18-039048 · tv498850_form4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.10 to $47.40, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,000 | $47.95 | $191,800.00 |
DisclosureSEC source: 0001144204-18-039048 · tv498850_form4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 34,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.75 to $48.40, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 17, 2018 Filed Jul 20, 2018 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 17,470 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-039048 · tv498850_form4.xml · derivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,318,034 Underlying: Class A Common Stock · 17,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. Read SEC document |
| July 17, 2018 Filed Jul 20, 2018 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 9,470 | $48.20 | $456,454.00 |
DisclosureSEC source: 0001144204-18-039048 · tv498850_form4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 38,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.95 to $48.50, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 17, 2018 Filed Jul 20, 2018 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 17,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-039048 · tv498850_form4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 47,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFICo., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficialownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 00:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $46.89 | $468,900.00 |
DisclosureSEC source: 0001144204-18-038034 · tv498336_form4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.45 to $47.20, inclusive. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 00:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $46.81 | $468,100.00 |
DisclosureSEC source: 0001144204-18-038034 · tv498336_form4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 40,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.45 to $47.25, inclusive. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 00:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-038034 · tv498336_form4.xml · derivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,335,504 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 00:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $46.96 | $469,600.00 |
DisclosureSEC source: 0001144204-18-038034 · tv498336_form4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 50,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.70 to $47.35, inclusive. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 00:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-038034 · tv498336_form4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 29, 2018 Filed Jun 30, 2018 01:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $45.65 | $456,500.00 |
DisclosureSEC source: 0001144204-18-036764 · tv497555_form4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.25 to $46.05, inclusive. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 28, 2018 Filed Jun 30, 2018 01:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $45.54 | $455,400.00 |
DisclosureSEC source: 0001144204-18-036764 · tv497555_form4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 40,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.10 to $46.00, inclusive. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 27, 2018 Filed Jun 30, 2018 01:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-036764 · tv497555_form4.xml · derivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,365,504 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. Read SEC document |
| June 27, 2018 Filed Jun 30, 2018 01:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $45.79 | $457,900.00 |
DisclosureSEC source: 0001144204-18-036764 · tv497555_form4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 50,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.40 to $46.25, inclusive. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 27, 2018 Filed Jun 30, 2018 01:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-036764 · tv497555_form4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 01:06 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 100 | $48.05 | $4,805.00 |
DisclosureSEC source: 0001144204-18-035215 · tv496773_form4.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 01:06 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 9,900 | $47.60 | $471,240.00 |
DisclosureSEC source: 0001144204-18-035215 · tv496773_form4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,100 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.98, inclusive. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 01:06 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $47.72 | $477,200.00 |
DisclosureSEC source: 0001144204-18-035215 · tv496773_form4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 40,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.45 to $48.03, inclusive. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 19, 2018 Filed Jun 22, 2018 01:06 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-035215 · tv496773_form4.xml · derivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,395,504 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. Read SEC document |
| June 19, 2018 Filed Jun 22, 2018 01:06 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $47.35 | $473,500.00 |
DisclosureSEC source: 0001144204-18-035215 · tv496773_form4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 50,000 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.10 to $47.75, inclusive. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 19, 2018 Filed Jun 22, 2018 01:06 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-035215 · tv496773_form4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 01:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $46.60 | $466,000.00 |
DisclosureSEC source: 0001144204-18-034115 · tv496295_form4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 30,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.15 to $47.05, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 01:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 32,530 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-034115 · tv496295_form4.xml · derivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,425,504 Underlying: Class A Common Stock · 32,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F4 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. F4 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 01:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 10,000 | $46.26 | $462,600.00 |
DisclosureSEC source: 0001144204-18-034115 · tv496295_form4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 40,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.05 to $46.60, inclusive. F3 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.